Unity Biotechnology, Inc. (UBX)

1,4800 +0,0100 (+0,68%) In data: 11:46AM EDT. Mercato aperto.

Unity Biotechnology, Inc.

285 East Grand Avenue
South San Francisco, CA 94080
United States
650 416 1192
https://unitybiotechnology.com

Settore/i: Healthcare
Settore: Biotechnology
Impiegati a tempo pieno: 19

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Dr. Anirvan Ghosh Ph.D.	CEO & Director	1,08M	N/D	1964
Dr. Nathaniel E. David A.B., Ph.D.	Co-Founder & Executive Director	40k	N/D	1968
Ms. Lynne Marie Sullivan	CFO & Head of Corporate Development	730,82k	N/D	1967
Dr. Jan M. van Deursen	Founder	N/D	N/D	N/D
Dr. Judith Campisi Ph.D.	Founder	N/D	N/D	N/D
Mr. Daohong Zhou M.D.	Founder	N/D	N/D	N/D
Mr. Alexander Hieu Nguyen J.D.	Chief Legal Officer, Head of Operations & Corporate Secretary	N/D	N/D	1978
Dr. Przemyslaw Sapieha Ph.D.	Chief Scientist	N/D	N/D	N/D
Ms. Sharon Klier M.D., M.P.H.	Head of Ophthalmology & Chief Development Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.

Governance aziendale

L'ISS Governance QualityScore di Unity Biotechnology, Inc. al 1 aprile 2024 è 10. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 9; diritti degli azionisti: 8; retribuzione: 10.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.